Alder Biopharma Cmn (ALDR) 33.97 $ALDR Alder Bi
Post# of 273254
Posted On: 09/24/2016 9:03:07 AM
Alder Biopharma Cmn (ALDR) 33.97 $ALDR
Alder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President of Regulatory Affairs and Pharmacovigilance
GlobeNewswire - Wed Sep 21, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Nancy L. Boman, M.D., Ph.D. as senior vice president of regulatory affairs and pharmacovigilance. Dr. Boman will be responsible for developing and implementing the regulatory strategy and pharmacovigilance program of ALD403 for migraine prevention as it advances through pivotal trials and toward a planned Biologic License Application (BLA) with the U.S. Food and Drug Administration (FDA).
ALDR: 33.97 (-0.33)
InvestorsObserver releases covered-call reports for Alder Biopharmaceuticals, bluebird bio Inc., Expedia, Amgen and Computer Sciences Corporation
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ALDR, AMGN, BLUE, CSC, and EXPE.
BLUE: 71.68 (-1.62), ALDR: 33.97 (-0.33), CSC: 51.57 (-0.30), EXPE: 109.91 (+1.12), AMGN: 174.80 (-0.82)
Alder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress
GlobeNewswire - Thu Sep 15, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine as well as preclinical data from a case study of ALD403 and other CGRP-antibodies at the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) in Glasgow, Scotland.
ALDR: 33.97 (-0.33)
Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention
GlobeNewswire - Thu Sep 08, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 supporting development for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies will be presented at the upcoming 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) on September 15-18, 2016 in Glasgow, U.K.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer
GlobeNewswire - Tue Sep 06, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Elisabeth A. Sandoval as chief commercial officer. Ms. Sandoval will be responsible for the further development and execution of the commercial strategy for ALD403, the company's pivotal-stage product candidate for the prevention of migraine.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences
GlobeNewswire - Wed Aug 31, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of the following upcoming healthcare conferences:
ALDR: 33.97 (-0.33), WFC: 45.74 (+0.02)
Under Armour, Starbucks, Alder Biopharmaceuticals, YY, and Google and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Aug 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ALDR, GOOGL, SBUX, UA, and YY.
SBUX: 54.43 (+0.04), UA: 39.45 (-0.45), ALDR: 33.97 (-0.33), YY: 54.15 (-0.66), GOOGL: 814.96 (-0.99)
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 9.6%
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 7:25AM CDT
Alder Biopharmaceuticals Inc. (ALDR) moved big last session, as its shares jumped almost 10% on the day.
ALDR: 33.97 (-0.33), GERN: 2.20 (-0.02)
How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma
PR Newswire - Wed Aug 10, 7:20AM CDT
Despite regulatory concerns, M&A activities are expected to continue pushing some Biotech stocks to new highs. The industry belongs in the Healthcare sector which was up by 0.6% on Tuesday, August 09, 2016. Stock-Callers.com takes a look at today's featured companies and see how they fared at the close: bluebird bio Inc. (NASDAQ: BLUE), Sage Therapeutics Inc. (NASDAQ: SAGE), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). Register now and get full and free access to our downloadable research reports on these stocks at:
BLUE: 71.68 (-1.62), ALDR: 33.97 (-0.33), SAGE: 46.54 (+0.72), RARE: 72.60 (-1.45)
Interesting ALDR Put And Call Options For August 19th
DividendChannel.com - Tue Jun 21, 9:57AM CDT
Investors in Alder Biopharmaceuticals Inc saw new options become available this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALDR options chain for the new August 19th contracts...
ALDR: 33.97 (-0.33)
Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies at the 58th Annual Scientific Meeting of the American Headache Society in San Diego.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Appoints Roger Cady, M.D., Vice President of Neurology
GlobeNewswire - Mon Jun 06, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Roger K. Cady, M.D. as vice president of neurology.
ALDR: 33.97 (-0.33)
Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies will be presented at the upcoming 58th Annual Scientific Meeting of the American Headache Society on June 9-12, 2016 in San Diego.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals to Present at Two Upcoming June Events
GlobeNewswire - Thu May 26, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Jefferies 2016 Healthcare Conference at 9:30 a.m. ET on Tuesday, June 7, 2016 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention
GlobeNewswire - Wed May 25, 7:08AM CDT
Iqbal Husain, Ph.D., Appointed Vice President of Program and Portfolio Management
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Fri May 06, 7:15AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Bank of America Merrill Lynch 2016 Health Care Conference at 10:00 a.m. PT (1:00 p.m. ET) on Wednesday, May 11, 2016 in Las Vegas, NV. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Licenses Clazakizumab Rights to Vitaeris
GlobeNewswire - Fri May 06, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, and Vitaeris Inc., a newly formed company that will pursue innovative therapeutic indications in chronic inflammatory diseases, today announced that Alder has licensed the exclusive worldwide rights to clazakizumab to Vitaeris. In exchange for the rights to clazakizumab, Alder has received an equity stake in Vancouver, British Columbia, based Vitaeris and is eligible to receive royalties and certain other payments. In addition, Randall C. Schatzman, Ph.D., president and chief executive officer of Alder, has joined Vitaeris' board of directors. Specific financial and other terms of the transaction were not disclosed.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Reports First Quarter 2016 Financial and Operating Results
GlobeNewswire - Thu Apr 28, 3:06PM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2016 Financial and Operating Results
GlobeNewswire - Thu Apr 21, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2016 financial and operating results after the close of U.S. financial markets on Thursday, April 28, 2016. Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
ALDR: 33.97 (-0.33)
Rheumatoid Arthritis Pipeline Review, H2 2015 - 200+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mc73g7/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Rheumatoid ArthritisOverview - Therapeutics Development - Pipeline Products for Rheumatoid Arthritis - Overview - Pipeline Products for Rheumatoid Arthritis - Comparative Analysis - Rheumatoid Arthritis - Therapeutics under Development by Companies - Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes - Rheumatoid Arthritis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Rheumatoid Arthritis - Products under Development by Companies - Rheumatoid Arthritis - Products under Investigation by Universities/Institutes - Rheumatoid Arthritis - Companies Involved in Therapeutics Development Companies Mentioned - 30 of the 200 Companies Featured - 3SBio Inc. - 4D Pharma Plc - 4SC AG - AB Science SA - AB2 Bio Ltd. - AbbVie Inc. - Ablynx NV - ACEA Biosciences, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegera Therapeutics Inc. - Alder Biopharmaceuticals Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Limited - Aprogen, Inc. - Arena Pharmaceuticals, Inc. - arGentis Pharmaceuticals, LLC - Arrien Pharmaceuticals, LLC - Arthrogen BV - Asahi Kasei Pharma Corp. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Avesthagen Limited - Avexxin AS - Axxam SpA - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited For more information visit http://www.researchandmarkets.com/research/mc73g7/rheumatoid
ALDR: 33.97 (-0.33), AZN: 33.97 (-0.31), AMGN: 174.80 (-0.82), ABBV: 64.98 (-0.10), ARNA: 1.74 (-0.03)
Alder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President of Regulatory Affairs and Pharmacovigilance
GlobeNewswire - Wed Sep 21, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Nancy L. Boman, M.D., Ph.D. as senior vice president of regulatory affairs and pharmacovigilance. Dr. Boman will be responsible for developing and implementing the regulatory strategy and pharmacovigilance program of ALD403 for migraine prevention as it advances through pivotal trials and toward a planned Biologic License Application (BLA) with the U.S. Food and Drug Administration (FDA).
ALDR: 33.97 (-0.33)
InvestorsObserver releases covered-call reports for Alder Biopharmaceuticals, bluebird bio Inc., Expedia, Amgen and Computer Sciences Corporation
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ALDR, AMGN, BLUE, CSC, and EXPE.
BLUE: 71.68 (-1.62), ALDR: 33.97 (-0.33), CSC: 51.57 (-0.30), EXPE: 109.91 (+1.12), AMGN: 174.80 (-0.82)
Alder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress
GlobeNewswire - Thu Sep 15, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine as well as preclinical data from a case study of ALD403 and other CGRP-antibodies at the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) in Glasgow, Scotland.
ALDR: 33.97 (-0.33)
Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention
GlobeNewswire - Thu Sep 08, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 supporting development for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies will be presented at the upcoming 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) on September 15-18, 2016 in Glasgow, U.K.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer
GlobeNewswire - Tue Sep 06, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Elisabeth A. Sandoval as chief commercial officer. Ms. Sandoval will be responsible for the further development and execution of the commercial strategy for ALD403, the company's pivotal-stage product candidate for the prevention of migraine.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences
GlobeNewswire - Wed Aug 31, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of the following upcoming healthcare conferences:
ALDR: 33.97 (-0.33), WFC: 45.74 (+0.02)
Under Armour, Starbucks, Alder Biopharmaceuticals, YY, and Google and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Aug 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ALDR, GOOGL, SBUX, UA, and YY.
SBUX: 54.43 (+0.04), UA: 39.45 (-0.45), ALDR: 33.97 (-0.33), YY: 54.15 (-0.66), GOOGL: 814.96 (-0.99)
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 9.6%
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 7:25AM CDT
Alder Biopharmaceuticals Inc. (ALDR) moved big last session, as its shares jumped almost 10% on the day.
ALDR: 33.97 (-0.33), GERN: 2.20 (-0.02)
How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma
PR Newswire - Wed Aug 10, 7:20AM CDT
Despite regulatory concerns, M&A activities are expected to continue pushing some Biotech stocks to new highs. The industry belongs in the Healthcare sector which was up by 0.6% on Tuesday, August 09, 2016. Stock-Callers.com takes a look at today's featured companies and see how they fared at the close: bluebird bio Inc. (NASDAQ: BLUE), Sage Therapeutics Inc. (NASDAQ: SAGE), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). Register now and get full and free access to our downloadable research reports on these stocks at:
BLUE: 71.68 (-1.62), ALDR: 33.97 (-0.33), SAGE: 46.54 (+0.72), RARE: 72.60 (-1.45)
Interesting ALDR Put And Call Options For August 19th
DividendChannel.com - Tue Jun 21, 9:57AM CDT
Investors in Alder Biopharmaceuticals Inc saw new options become available this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALDR options chain for the new August 19th contracts...
ALDR: 33.97 (-0.33)
Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies at the 58th Annual Scientific Meeting of the American Headache Society in San Diego.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Appoints Roger Cady, M.D., Vice President of Neurology
GlobeNewswire - Mon Jun 06, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Roger K. Cady, M.D. as vice president of neurology.
ALDR: 33.97 (-0.33)
Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies will be presented at the upcoming 58th Annual Scientific Meeting of the American Headache Society on June 9-12, 2016 in San Diego.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals to Present at Two Upcoming June Events
GlobeNewswire - Thu May 26, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Jefferies 2016 Healthcare Conference at 9:30 a.m. ET on Tuesday, June 7, 2016 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention
GlobeNewswire - Wed May 25, 7:08AM CDT
Iqbal Husain, Ph.D., Appointed Vice President of Program and Portfolio Management
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Fri May 06, 7:15AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Bank of America Merrill Lynch 2016 Health Care Conference at 10:00 a.m. PT (1:00 p.m. ET) on Wednesday, May 11, 2016 in Las Vegas, NV. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Licenses Clazakizumab Rights to Vitaeris
GlobeNewswire - Fri May 06, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, and Vitaeris Inc., a newly formed company that will pursue innovative therapeutic indications in chronic inflammatory diseases, today announced that Alder has licensed the exclusive worldwide rights to clazakizumab to Vitaeris. In exchange for the rights to clazakizumab, Alder has received an equity stake in Vancouver, British Columbia, based Vitaeris and is eligible to receive royalties and certain other payments. In addition, Randall C. Schatzman, Ph.D., president and chief executive officer of Alder, has joined Vitaeris' board of directors. Specific financial and other terms of the transaction were not disclosed.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals Reports First Quarter 2016 Financial and Operating Results
GlobeNewswire - Thu Apr 28, 3:06PM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016.
ALDR: 33.97 (-0.33)
Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2016 Financial and Operating Results
GlobeNewswire - Thu Apr 21, 7:00AM CDT
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2016 financial and operating results after the close of U.S. financial markets on Thursday, April 28, 2016. Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
ALDR: 33.97 (-0.33)
Rheumatoid Arthritis Pipeline Review, H2 2015 - 200+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mc73g7/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Rheumatoid ArthritisOverview - Therapeutics Development - Pipeline Products for Rheumatoid Arthritis - Overview - Pipeline Products for Rheumatoid Arthritis - Comparative Analysis - Rheumatoid Arthritis - Therapeutics under Development by Companies - Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes - Rheumatoid Arthritis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Rheumatoid Arthritis - Products under Development by Companies - Rheumatoid Arthritis - Products under Investigation by Universities/Institutes - Rheumatoid Arthritis - Companies Involved in Therapeutics Development Companies Mentioned - 30 of the 200 Companies Featured - 3SBio Inc. - 4D Pharma Plc - 4SC AG - AB Science SA - AB2 Bio Ltd. - AbbVie Inc. - Ablynx NV - ACEA Biosciences, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegera Therapeutics Inc. - Alder Biopharmaceuticals Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Limited - Aprogen, Inc. - Arena Pharmaceuticals, Inc. - arGentis Pharmaceuticals, LLC - Arrien Pharmaceuticals, LLC - Arthrogen BV - Asahi Kasei Pharma Corp. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Avesthagen Limited - Avexxin AS - Axxam SpA - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited For more information visit http://www.researchandmarkets.com/research/mc73g7/rheumatoid
ALDR: 33.97 (-0.33), AZN: 33.97 (-0.31), AMGN: 174.80 (-0.82), ABBV: 64.98 (-0.10), ARNA: 1.74 (-0.03)
(0)
(0)Scroll down for more posts ▼